TARA - ArTara Therapeutics Inc Stock Price, Fair Value and News

2.91USD-0.14 (-4.59%)Market Closed

Market Summary

USD2.91-0.14

Market Closed

-4.59%

TARA Alerts

CITADEL ADVISORS LLC reported owning 5.7% of TARA [2024-04-22]

TARA Stock Price

View Fullscreen

TARA RSI Chart

TARA Valuation

Market Cap

33.3M

Price/Earnings (Trailing)

-0.82

Price/Sales (Trailing)

159.29

Price/Free Cashflow

-0.88

TARA Price/Sales (Trailing)

TARA Profitability

Return on Equity

-59.16%

Return on Assets

-51.19%

Free Cashflow Yield

-113.01%

TARA Fundamentals

TARA Revenue

Revenue (TTM)

262.0K

TARA Earnings

Earnings (TTM)

-40.4M

Earnings Growth (Yr)

73.77%

Earnings Growth (Qtr)

-3.66%

Breaking Down TARA Revenue

Last 7 days

10.2%

Last 30 days

-27.3%

Last 90 days

11.9%

Trailing 12 Months

-9.9%

How does TARA drawdown profile look like?

TARA Financial Health

Current Ratio

11.17

TARA Investor Care

Shares Dilution (1Y)

1.12%

Diluted EPS (TTM)

-3.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	449.0K	416.0K	356.0K	262.0K
2018	319.0K	379.0K	409.0K	436.0K
2017	169.0K	162.0K	199.0K	259.0K
2016	160.0K	176.0K	188.0K	193.0K
2015	2.2M	1.5M	845.0K	144.0K
2014	0	0	0	2.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ArTara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 19, 2024	shefferman jesse	acquired	-	-	59,000	ceo and president
Jan 19, 2024	bandari jathin	acquired	-	-	23,000	chief medical officer
Jan 19, 2024	zummo jacqueline	sold (taxes)	-5,823	1.91	-3,049	chf scientific operations off
Jan 19, 2024	fry hannah	sold (taxes)	-1,726	1.91	-904	vp, controller
Jan 19, 2024	fry hannah	acquired	-	-	8,000	vp, controller
Jan 19, 2024	bandari jathin	sold (taxes)	-5,498	1.91	-2,879	chief medical officer
Jan 19, 2024	fabbio patrick	acquired	-	-	22,000	chief financial officer
Jan 19, 2024	shefferman jesse	sold (taxes)	-14,903	1.91	-7,803	ceo and president
Jan 19, 2024	zummo jacqueline	acquired	-	-	23,000	chf scientific operations off
Jan 10, 2024	zummo jacqueline	sold (taxes)	-12,497	2.39	-5,229	chf scientific operations off

Which funds bought or sold TARA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	71,000	71,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	unchanged	-	38,230	71,807	-%
Apr 24, 2024	Assenagon Asset Management S.A.	sold off	-100	-29,685	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	87,703	801,815	-%
Feb 14, 2024	ORBIMED ADVISORS LLC	sold off	-100	-1,290,220	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	12,800	119,680	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-8.05	1,483	47,149	-%
Feb 14, 2024	BAKER BROS. ADVISORS LP	unchanged	-	40,952	374,403	-%

Are Funds Buying or Selling TARA?

Are funds buying TARA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TARA

No. of Funds

TARA Alerts

CITADEL ADVISORS LLC reported owning 5.7% of TARA [2024-04-22]

Unveiling ArTara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	ra capital management, l.p.	9.99%	2,073,075	SC 13G
Apr 22, 2024	citadel advisors llc	5.7%	6	SC 13G
Apr 09, 2024	cvi investments, inc.	5.3%	600,380	SC 13G
Feb 14, 2024	orbimed advisors llc	0.0%	0	SC 13G/A
Feb 14, 2023	orbimed advisors llc	6.0%	671,741	SC 13G/A
Feb 15, 2022	perceptive advisors llc	3.8%	421,641	SC 13G/A
Feb 15, 2022	rock springs capital management lp	0.00%	0	SC 13G/A
Feb 14, 2022	ikarian capital, llc	2.5%	279,256	SC 13G/A
Feb 11, 2022	orbimed advisors llc	6.0%	671,741	SC 13G
Feb 16, 2021	perceptive advisors llc	5.4%	608,544	SC 13G/A

Recent SEC filings of ArTara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	SC 13G	Major Ownership Report
Apr 22, 2024	SC 13G	Major Ownership Report
Apr 09, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 14, 2024	S-8	Employee Benefits Plan
Mar 13, 2024	10-K	Annual Report

Peers (Alternatives to ArTara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

ArTara Therapeutics Inc News

Latest updates

ArTara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4
Revenue	-41.5%	31.00	53.00	73.00	105	125	113	106	92.00	98.00	83.00	46.00	32.00	38.00	46.00	53.00	56.00	33.00	34.00	37.00	1,007	1,978
Operating Expenses	7.0%	2,519	2,354	1,429	1,528	5,385	4,622	5,000	6,365	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	43.7%	1,804	1,255	442	450	2,722	2,268	2,240	2,294	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-34.9%	715	1,099	987	1,078	2,663	2,354	2,760	4,071	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	2.0%	-56.65*	-57.80*	-49.47*	-45.83*	-47.19*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00
EBT Margin	1.7%	-57.22*	-58.23*	-49.83*	-46.17*	-47.54*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.0%	-2,519	-2,354	-1,428	-1,528	-5,259	-4,510	-4,879	-6,081	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.8%	79.00	88.00	95.00	106	113	149	155	161	173	181	189	192	203	199	63.00	70.00	40.00	10.00	12.00	18.00	24.00
Current Assets	-11.7%	69.00	78.00	84.00	95.00	86.00	99.00	101	91.00	93.00	96.00	88.00	88.00	169	167	33.00	40.00	1.00	10.00	11.00	18.00	23.00
Cash Equivalents	17.2%	40.00	34.00	34.00	21.00	24.00	48.00	35.00	26.00	36.00	41.00	48.00	59.00	169	166	30.00	36.00	1.00	2.00	3.00	4.00	6.00
Net PPE	-7.5%	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00	-	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	29.00	30.00	-	-	-	-
Liabilities	-7.6%	11.00	12.00	10.00	12.00	11.00	9.00	9.00	9.00	11.00	10.00	10.00	4.00	4.00	4.00	4.00	5.00	3.00	2.00	2.00	3.00	3.00
Current Liabilities	-9.2%	6.00	7.00	5.00	6.00	6.00	4.00	3.00	3.00	4.00	4.00	4.00	3.00	3.00	4.00	3.00	5.00	3.00	2.00	2.00	3.00	3.00
Shareholder's Equity	-11.2%	68.00	77.00	85.00	95.00	102	139	145	152	162	170	178	188	199	195	59.00	65.00	6.00	0.00	2.00	3.00	5.00
Retained Earnings	-5.4%	-200	-190	-180	-169	-159	-121	-113	-104	-94.01	-83.78	-73.01	-60.22	-46.76	-37.95	-29.98	-22.84	-12.78	-223	-222	-217	-210
Additional Paid-In Capital	0.5%	269	267	266	264	263	261	260	258	256	254	252	249	246	233	89.00	88.00	11.00	211	211	210	209
Accumulated Depreciation	-	1.00	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0%	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	18.00	-	-	-	20.00	-	-	-	74.00	-	-	-	77.00	-	-	-	6.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-32.6%	-8,700	-6,561	-9,408	-12,888	-5,026	-5,347	-5,123	-10,961	-6,907	-6,201	-9,474	-11,920	-6,766	-3,762	-5,733	-7,146	-1,088	-1,212	-1,303	-1,406	-4,313
Share Based Compensation	0.3%	1,452	1,447	1,618	1,575	1,430	1,437	1,942	1,879	1,908	2,716	2,998	2,740	2,339	2,781	1,829	2,798	106	139	102	77.00	782
Cashflow From Investing	127.6%	14,518	6,378	22,351	9,860	-18,345	19,048	13,502	745	1,889	107	-1,941	-98,249	-511	-132	6.00	3,472	-45.86	-325	-76.62	-27.11	5,413
Cashflow From Financing	100.0%	-	-27.00	-	-64.00	-	-18.00	-	-72.00	-	-	-	-228	10,715	139,828	-371	39,229	1*	-	-	-	48.00
Buy Backs	-100.0%	-	27.00	-	64.00	-	18.00	-	72.00	-	-	-	228	-	-	-	-	-	-	-	-	-

TARA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 24,989	$ 16,808
General and administrative	18,624	20,737
Loss on impairment of goodwill		29,517
Total operating expenses	43,613	67,062
Loss from operations	(43,613)	(67,062)
Other income (expense), net:
Interest and investment income	3,193	1,110
Other income (expense), net	3,193	1,110
Net loss	$ (40,420)	$ (65,952)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (3.57)	$ (5.86)
Weighted average shares outstanding, basic (in Shares)	11,331,338	11,259,615
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities	$ 657	$ (477)
Other comprehensive income (loss)	657	(477)
Comprehensive loss	$ (39,763)	$ (66,429)

TARA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,586	$ 24,127
Marketable debt securities	25,994	60,243
Prepaid expenses and other current assets	3,125	1,776
Total current assets	68,705	86,146
Restricted cash, non-current	745	745
Marketable debt securities, non-current		17,886
Property and equipment, net	1,296	1,592
Operating lease right-of-use asset	5,264	6,277
Other assets	2,944	644
Total assets	78,954	113,290
Current liabilities:
Accounts payable	2,434	1,586
Accrued expenses	2,732	3,237
Operating lease liability	983	917
Total current liabilities	6,149	5,740
Operating lease liability, non-current	4,484	5,467
Total liabilities	10,633	11,207
Commitments and contingencies (Note 10)
Stockholders’ Equity:
Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2023 and 2022, 7,991 and 8,027 shares issued and outstanding as of December 31, 2023 and 2022, respectively.
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,364,903 and 11,267,389 shares issued and outstanding as of December 31, 2023 and 2022, respectively.	11	11
Additional paid in capital	268,725	262,724
Accumulated deficit	(200,384)	(159,964)
Accumulated other comprehensive income (loss)	(31)	(688)
Total stockholders’ equity	68,321	102,083
Total liabilities and stockholders’ equity	$ 78,954	$ 113,290

About ArTara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

CEO	Mr. Jesse Shefferman
WEBSITE	protaratx.com
INDUSTRY	Biotechnology
EMPLOYEES	25

ArTara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for ArTara Therapeutics Inc? What does TARA stand for in stocks?

TARA is the stock ticker symbol of ArTara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ArTara Therapeutics Inc (TARA)?

As of Fri Apr 26 2024, market cap of ArTara Therapeutics Inc is 33.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARA stock?

You can check TARA's fair value in chart for subscribers.

What is the fair value of TARA stock?

You can check TARA's fair value in chart for subscribers. The fair value of ArTara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ArTara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TARA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ArTara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TARA is over valued or under valued. Whether ArTara Therapeutics Inc is cheap or expensive depends on the assumptions which impact ArTara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARA.

What is ArTara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TARA's PE ratio (Price to Earnings) is -0.82 and Price to Sales (PS) ratio is 159.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARA PE ratio will change depending on the future growth rate expectations of investors.